First Horizon Advisors’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$1.53M Sell
12,677
-2,262
-15% -$255K 0.04% 221
2025
Q1
$1.67M Buy
14,939
+494
+3% +$52.6K 0.05% 212
2024
Q4
$1.41M Buy
14,445
+56
+0.4% +$5.97K 0.04% 224
2024
Q3
$1.66M Buy
14,389
+323
+2% +$36.6K 0.05% 217
2024
Q2
$1.5M Buy
14,066
+2,439
+21% +$245K 0.05% 220
2024
Q1
$1.12M Sell
11,627
-48
-0.4% -$4.92K 0.03% 234
2023
Q4
$1.18M Sell
11,675
-287
-2% -$27.7K 0.04% 234
2023
Q3
$1.22M Sell
11,962
-10
-0.1% -$1.01K 0.04% 226
2023
Q2
$1.21M Buy
11,972
+103
+0.9% +$10.3K 0.04% 242
2023
Q1
$1.09M Sell
11,869
-283
-2% -$24.7K 0.04% 248
2022
Q4
$1.1M Sell
12,152
-1,826
-13% -$154K 0.04% 249
2022
Q3
$1.06M Sell
13,978
-892
-6% -$73.9K 0.04% 243
2022
Q2
$1.26M Sell
14,870
-230
-2% -$20.2K 0.04% 240
2022
Q1
$1.32M Sell
15,100
-1,461
-9% -$126K 0.07% 209
2021
Q4
$1.45M Sell
16,561
-2,543
-13% -$211K 0.04% 250
2021
Q3
$1.56M Buy
19,104
+11,912
+166% +$1.07M 0.05% 239
2021
Q2
$655K Sell
7,192
-6,923
-49% -$616K 0.04% 232
2021
Q1
$1.21M Sell
14,115
-63,482
-82% -$5.7M 0.07% 177
2020
Q4
$7.33M Buy
77,597
+3,298
+4% +$288K 0.49% 61
2020
Q3
$6.46M Buy
74,299
+2,963
+4% +$257K 0.48% 66
2020
Q2
$6.23M Buy
71,336
+5,207
+8% +$449K 0.49% 62
2020
Q1
$5.45M Buy
66,129
+5,869
+10% +$524K 0.51% 60
2019
Q4
$5.71M Buy
60,260
+3,342
+6% +$300K 0.42% 70
2019
Q3
$4.95M Buy
56,918
+763
+1% +$68.5K 0.39% 78
2019
Q2
$5.13M Sell
56,155
-1,255
-2% -$106K 0.4% 73
2019
Q1
$4.95M Buy
57,410
+6,030
+12% +$484K 0.4% 69
2018
Q4
$3.95M Buy
51,380
+5,132
+11% +$399K 0.35% 71
2018
Q3
$3.57M Buy
46,248
+2,125
+5% +$157K 0.28% 100
2018
Q2
$2.98M Buy
44,123
+2,609
+6% +$180K 0.25% 114
2018
Q1
$3.01M Buy
41,514
+2,886
+7% +$220K 0.29% 96
2017
Q4
$2.94M Buy
38,628
+1,775
+5% +$134K 0.28% 97
2017
Q3
$2.84M Sell
36,853
-212
-0.6% -$16K 0.29% 96
2017
Q2
$2.78M Buy
37,065
+1,973
+6% +$140K 0.3% 95
2017
Q1
$2.38M Buy
35,092
+6,644
+23% +$443K 0.27% 99
2016
Q4
$1.97M Hold
28,448
0.25% 111
2016
Q3
$1.97M Sell
28,448
-1,719
-6% -$125K 0.25% 111
2016
Q2
$2.23M Buy
30,167
+1,076
+4% +$74.3K 0.3% 102
2016
Q1
$1.9M Buy
29,091
+2,431
+9% +$165K 0.21% 110
2015
Q4
$2.05M Sell
26,660
-3,331
-11% -$265K 0.36% 89
2015
Q3
$2.47M Sell
29,991
-4,705
-14% -$419K 0.38% 95
2015
Q2
$3.06M Sell
34,696
-2,119
-6% -$194K 0.44% 87
2015
Q1
$3.31M Sell
36,815
-1,858
-5% -$165K 0.48% 76
2014
Q4
$3.22M Buy
38,673
+267
+0.7% +$22.1K 0.5% 68
2014
Q3
$3.24M Buy
38,406
+1,055
+3% +$85.4K 0.51% 67
2014
Q2
$2.94M Buy
37,351
+5,289
+16% +$416K 0.43% 82
2014
Q1
$2.42M Buy
32,062
+3,480
+12% +$254K 0.34% 86
2013
Q4
$1.96M Buy
28,582
+7,974
+39% +$554K 0.29% 88
2013
Q3
$1.42M Buy
20,608
+11,212
+119% +$742K 0.23% 105
2013
Q2
$595K Buy
+9,396
New +$611K 0.3% 43

Other funds holding NVS

First Horizon Advisors's NVS Position: Q2 2025 in Review

First Horizon Advisors reduced its Novartis (NVS) stake by 15% in Q2 2025, selling an estimated $255K and leaving 12,677 shares worth $1.53M. The position accounts for 0.04% of the portfolio, ranked #221.

First Horizon Advisors first reported a position in NVS in Q2 2013 and has held it in 49 quarters since. The position peaked at $7.33M in Q4 2020. 1,384 funds tracked by Wall St. Rank hold NVS as of Q2 2025.

  • First Horizon Advisors held 12,677 shares of Novartis worth $1.53M as of Q2 2025.
  • First Horizon Advisors sold 2,262 Novartis shares in Q2 2025, an estimated $255K.
  • Novartis made up 0.04% of First Horizon Advisors's portfolio in Q2 2025, its #221 holding.
  • First Horizon Advisors first reported a position in Novartis in Q2 2013 and has held it in 49 quarters since.
  • First Horizon Advisors's Novartis position peaked at $7.33M in Q4 2020.
  • 1,384 funds tracked by Wall St. Rank held Novartis as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.